Hoffman Richard M
Medicine Service, Albuquerque Veterans Affairs Medical Center, 1501 San Pedro Dr. SE, Albuquerque, NM 87108, USA.
J Natl Cancer Inst Monogr. 2012 Dec;2012(45):197-201. doi: 10.1093/jncimonographs/lgs023.
Treatment decisions for localized prostate cancer are preference sensitive. The optimal treatment strategy is unknown, and active treatment is not always necessary. Choosing among the various options involves tradeoffs between cancer control and complications that affect quality of life. A shared decision-making process, particularly facilitated by a decision aid, can help a patient make an informed decision that is concordant with his values and preferences. Studies have shown that informed patients are more willing to forego aggressive treatment, but much work is needed to develop and evaluate high-quality decision aids that accurately portray active surveillance. The research agenda for decision aids includes evaluating content elements and format, timing and setting for delivery, the quality of the decision-making process, and the effects of decision support on treatment selection (which will occur repeatedly for men opting for active surveillance) and quality of life.
局限性前列腺癌的治疗决策具有偏好敏感性。最佳治疗策略尚不清楚,且并非总是需要积极治疗。在各种治疗方案中进行选择需要在癌症控制与影响生活质量的并发症之间进行权衡。一个共同决策的过程,特别是在决策辅助工具的帮助下,可以帮助患者做出符合其价值观和偏好的明智决策。研究表明,了解情况的患者更愿意放弃积极治疗,但仍需要开展大量工作来开发和评估能够准确描述主动监测的高质量决策辅助工具。决策辅助工具的研究议程包括评估内容要素和形式、提供的时间和环境、决策过程的质量,以及决策支持对治疗选择(对于选择主动监测的男性患者来说,这一过程会反复出现)和生活质量的影响。